
FDA First AI cGMP Warning Letter: Manufacturing Lessons
Examine the FDA's first warning letter for AI misuse in cGMP manufacturing. This review details compliance lessons and human oversight requirements for QA.
IntuitionLabs is now a member of the Claude Partner Network – AI training and upskilling with Claude for pharma and biotech. Book a call.

Examine the FDA's first warning letter for AI misuse in cGMP manufacturing. This review details compliance lessons and human oversight requirements for QA.

Learn best practices for writing an effective FDA 483 response. Updated with FY2024-2025 enforcement data and FDA's AI-driven inspection targeting. Covers CAPAs, timelines, and strategies to avoid Warning Letters.
© 2026 IntuitionLabs. All rights reserved.